Risk factors of morbidity of malignant pleural mesothelioma

Authors

  • Agata Sałek Z Oddziału Onkologii Klinicznej Podkarpackiego Centrum Onkologii Wojewódzkiego Szpitala Specjalistycznego w Rzeszowie
  • Bożenna Karczmarek-Borowska Z Zakładu Onkologii Wydziału Medycznego Uniwersytetu Rzeszowskiego https://orcid.org/0000-0002-2936-9616

Keywords:

risk factors, azbestos, malignant pleural mesothelioma

Abstract

Malignant pleural mesothelioma is the most frequently occurring type of pleural neoplasm. It is mainly diagnosed in men between 50 and 74 years of age. In Poland was recorded 250 new cases of this neoplasm in 2009. Asbestos fibre, especially crocidolite fibre, is the most common and the best known factor predisposing to the development of pleural mesothelioma. Asbestos is a set of 6 minerals, which due to its physical and chemical properties, used to be commonly implemented by industry. It has been proven, that the time and intensity of exposure to asbestos are what affect the formation of pleural mesothelioma. This exposure time ranges between 20 and 40 years. When the correlation between asbestos exposure and development of mesothelioma was first published, the International Labour Organization adopted a convention regulating safety in the use of products containing asbestos. As of year 2008, Poland implemented programs on asbestos removal as well as prevention and early mesothelioma diagnosis for individuals exposed to asbestos. Other provable factors, that predispose to the development of pleural mesothelioma are infection with Simon Virus 40, genetic susceptibility to erionite and exposure to ionizing radiation. The malignant pleural mesothelioma is characterized by relative low percentage of full recovery. Radical surgical treatment is possible in about 10% cases. Other patients are subjected to treatment aiming to prolong and improve the quality of life.

Downloads

Download data is not yet available.

References

Raporty na podstawie danych Centrum Onkologii. http://www.onkologia.org.pl/.

Yang H, Testa J, Carbone M. Mesothelioma Epidemiology, Carcinogenesis and Pathogenesis. Curr Treat Options Oncol. 2008; 9 (2-3): 147 -157.

Robinson B, Musk A, Lake R. Malignant mesothelioma. Lancet 2005;366:397–408.

Hai B, Yang Y, Xiao Y, et al. Diagnosis and prognosis of malignant mesothelioma of the tunica vaginalis testis. Can Urol Assoc J. 2011; 8:1-4.

Foltyn M. Azbest – kłopotliwa spuścizna. Bezpieczeństwo Pracy. Nauka i Praktyka. Centralny Instytut Ochrony Pracy– Państwowy Instytut Badawczy 4/2007: 16-19.

Szeszenia-Dąbrowska N, Sobala W. Zanieczyszczenie środowiska azbestem. Skutki zdrowotne. Raport z badań, wydanie II poprawione i uzupełnione IMP, Łódź 2010.

Dyczka J. (red): Bezpieczne postępowanie z azbestem i materiałami zawierającymi azbest. Wyd. Naukowe „Akapit”, Kraków 2007.

Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007;45(3):379-87.

Rozporządzenie Rady Ministrów z dnia 30 lipca 2002r. (Dz. U. Nr 132, 2002, poz. 115).

Restrepo C, Chen M, Martinez-Jimenez S, at al. Chest neoplasms with infectious etiologies. World J Radiol. 2011; 28; 3(12): 279–288.

Cutrone R, Lednicky J, Dunn G, et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 2005;6:10273–10279.

Boylan A. Mesothelioma : new concepts in diagnosis and management. Curr Opin Pulm Med 2000; 6: 157.

Carbone M, Emri S, Dogan A, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7:147–154.

Ustawa z dnia 19 czerwca 1997r. o zakazie stosowania wyrobów zawierających azbest (tj. Dz.U. 101, poz. 628 ze zmianami, Dz.U. z 1998r., Nr 156, poz. 1018).

Deja L, Dyczek J, Mastalski J. Poradnik dla użytkowników wyrobów azbestowych. Ministerstwo Gospodarki, Warszawa 2008.

Ustawa z dnia 19 czerwca 1997 r. o zakazie stosowania wyrobów zawierających azbest ( tj. Dz.U. 2004 nr 3, poz. 20).

Rozporządzenie Ministra Gospodarki, Pracy, Polityki Społecznej z dnia 2 kwietnia 2004r. w sprawie sposobów i warunków bezpiecznego użytkowania i usuwania wyrobów zawierających azbest( t.j. Dz.U. 2004 nr 71 poz. 649).

Rozporządzenie Ministra Gospodarki i Pracy z dnia 14 października 2005 r. w sprawie zasad bezpieczeństwa i higieny pracy przy zabezpieczaniu i usuwaniu wyrobów zawierających azbest oraz programu szkolenia w zakresie bezpiecznego użytkowania takich wyrobów (Dz. U. z dnia 31 października 2005 r.).

Markman M. (red): Atlas chorób nowotworowych. Tom 1. Wyd.Via Medica, Gdańsk 2009.

Domagała- Kulawik J, Olszewski W. Atlas cytopatologi układu oddechowego. Wyd. -medica press, 2009.

Krzakowski M. Postępy w leczeniu złośliwego międzybłoniaka opłucnej. Onkologia w Praktyce Klinicznej 2005; 1: 132-140.

Jassem J, Biernat W, Drosik K i wsp. Uaktualnione zalecenia dotyczące systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej. Nowotwory 2010; Nr 3: 258-270.

Z. Wang, G. Reddy, M. Gotway, at al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004; 24(1):105-19

Maziak D, Gagliardi A, Haynes A, at al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005; 48: 157–169.

Treasurea T, Lang-Lazdunskib L, Wallerd D, at all, and for the MARS trial list. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011; 12(8): 763–772.

Mesothelioma UK. MesoVATS Trial. http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-at-treatment-for-fluid-around-the-lung-caused-by-mesothelioma (25.01.2012).

Vogelzang N, Rusthoven J, Symanowski J, at al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636- 44.

Ball D, Cruickshank D. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990; 13:4-9.

Govindan R, Kratzke R, Herndon J, at al. Gefitynib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005; 11: 2300-2304.

Mathy A, Baas P, Dalesio O, at al. Limited efficacy of imatinib mesylate in malignant mesothelioma : a phase II trial. Lung Cancer 2005; 50: 83-86.

Dowell J, Kindler H. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am. 2005; 19: 1137-1145.

Downloads

Published

2012-12-30

How to Cite

Sałek, A., & Karczmarek-Borowska, B. (2012). Risk factors of morbidity of malignant pleural mesothelioma. European Journal of Clinical and Experimental Medicine, 10(4), 508–512. Retrieved from https://journals.ur.edu.pl/ejcem/article/view/12715

Issue

Vol. 10 No. 4 (2012): Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Section

REVIEW PAPERS

License

Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.